Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of GLP-1 or analogs in treatment of stroke

A technology of GLP-1 and analogues, applied in the field of application of GLP-1 or analogues in the treatment of stroke, can solve the problems of heavy burden on health care experts, increase the difficulty and cost of treatment, and achieve the goal of avoiding the risk of hypoglycemia and reducing the risk of hypoglycemia Effects on Small Infarct Size, Mortality, and Morbidity Reduction

Inactive Publication Date: 2001-11-14
ELI LILLY & CO
View PDF14 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Such a strong need to monitor blood glucose places a heavy burden on healthcare professionals, increasing the difficulty and cost of treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of GLP-1 or analogs in treatment of stroke
  • Use of GLP-1 or analogs in treatment of stroke

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0240] Example 1: Effect of subcutaneous infusion of GLP-1 (7-30) on blood glucose in NIDDM patients

[0241] GLP-1(7-36)amide was administered to five non-insulin-dependent diabetic (NIDDM) patients overnight by subcutaneous infusion for ten hours at a rate of 1.2 pmol / kg / hr. As a control, insulin was infused to the same five patients on a day when GLP-1(7-36)amide was not infused. The insulin infusion rate was adjusted every two hours to achieve optimal control and avoid hypoglycemia. Table 1 and figure 1 The data demonstrate that subcutaneous infusion of GLP-1(7-36)amide normalized blood glucose in almost all patients without inducing hypoglycemia. GLP-1(7-36) amide metabolism was better controlled than that achieved with insulin, at 23:00, 0:00 and 1:00, mean blood glucose levels were lower in GLP-1(7-36) amide treatment than in controls , with a statistically significant difference.

[0242] GLP-1 infusion

Embodiment 2

[0243] Example 2: Effect of subcutaneous infusion of GLP-1(7-36) during meals on blood glucose levels in NIDDM patients

[0244] Five NIDDM patients were infused with GLP-1(7-36)amide for three hours during breakfast, lunch and dinner on the day of the study. The infusion time is 7:30-10:30 (breakfast), 10:30-1:30 (lunch) and 4:30-7:30 (dinner), such as figure 2 shown. In a controlled experiment performed on the same five NIDDM patients on another day, insulin was injected subcutaneously shortly before the start of each meal, as figure 2 shown. The postprandial glucose excursion observed with insulin injections was abolished and normoglycemia was maintained when GLP-1 was infused. Blood glucose levels rose significantly immediately after each GLP-1(7-36)amide infusion was terminated. No counterproductive side effects of GLP-1(7-36)amide were observed. These data demonstrate that GLP-1(7-36)amide infusion controls postprandial glucose levels more effectively than insulin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention provides a method of reducing mortality and morbidity associated with stroke. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.

Description

[0001] The present invention relates to methods and compositions for reducing mortality and morbidity after stroke by controlling hyperglycemia. The methods and compositions are particularly useful for non-insulin-dependent diabetics who are at risk of new strokes, or who have had progressive or recurrent strokes. It not only cures existing hyperglycemia, but also prevents new hyperglycemia. Background of the invention [0002] Patients with overt diabetes or reduced glucose tolerance have higher cardiovascular morbidity and mortality than patients without these conditions. Diabetics account for 24% of the total number of patients admitted to coronary medical units for suspected myocardial infarction, yet they represent only about 5% of the general population (Fuller, 1993). Admission mortality in diabetic patients with myocardial infarction is twice that of non-diabetic patients (Hamsten, 1994, Malmberg and Ryden, 1988). Morbidity and mortality are higher in the recovery ph...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/04A61K38/26A61P3/10A61P9/10A61P25/00
CPCA61K38/26A61P25/00A61P3/10A61P9/10
Inventor S·埃芬迪克
Owner ELI LILLY & CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com